Tag: biopharmaceutical cm

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Biopharmaceutical CMO Market Change Between 2026 And 2030?

The biopharmaceutical cmo and cro market size has demonstrated significant growth in recent years. It is anticipated to increase from $35.6 billion in 2025 to $38.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical expansion can be attributed to several factors, including the increasing complexity of biologic drug development, rising R&D costs for biopharmaceutical companies, an expansion of clinical trial activities, the growth in biosimilar development, and the availability of specialized contract service providers.

The biopharmaceutical cmo and cro market is projected to experience robust expansion over the coming years. By 2030, its size is anticipated to reach $48.79 billion, growing at a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period stems from factors such as a heightened demand for sophisticated biologics manufacturing, increasing capital allocation towards cell and gene therapies, the broadening scope of global clinical trial pipelines, a sharpened emphasis on strategies to accelerate market entry, and the wider integration of digitalized CRO services. Key trends characterizing the forecast horizon encompass a rise in the outsourcing of biologic drug production, an escalating need for comprehensive end-to-end contract research services, a greater emphasis on adaptable manufacturing capabilities, an expansion in support for cell and gene therapy development, and a reinforced focus on regulatory compliance services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

Which Significant Factors Are Encouraging Growth In The Biopharmaceutical CMO Market?

Increased spending on research and development is projected to boost the expansion of the biopharmaceutical CMO and CRO market in the future. This surge in R&D funding stems from various elements, including a strong demand for novel solutions, intense competitive landscapes, the necessity to meet changing market requirements, and encouraging government policies. Such investments empower CMOs and CROs to develop improved manufacturing techniques and research methodologies, thereby enhancing their capabilities and operational effectiveness. This push for innovation attracts and retains customers by offering advanced solutions while simultaneously ensuring adherence to regulatory standards. For example, data from September 2025, supplied by Eurostat, the Luxembourg-based statistical agency, showed that the EU allocated approximately $456 billion USD towards research and development (R&D) in 2023 (€389 billion); this represented an increase in R&D expenditure relative to GDP, reaching 2.26% from 2.22% in the previous year. Consequently, the increasing financial commitment to research and development is fueling the expansion of the biopharmaceutical CMO and CRO market.

How Is The Biopharmaceutical CMO Market Distributed Across Key Segments?

The biopharmaceutical cmo market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Source: Mammalian, Non-Mammalian

3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

Subsegments:

1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

Which Trends Are Affecting The Biopharmaceutical CMO Market Framework?

Leading firms within the biopharmaceutical CMO and CRO market are establishing strategic alliances to bolster service offerings, boost operational effectiveness, and expedite drug development processes for biopharmaceutical entities. Such partnerships involve organizations utilizing one another’s capabilities and assets to secure shared advantages and successful outcomes. An example of this is the collaboration in June 2024 between Abzena plc., a biopharmaceutical firm from the UK, and Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), aimed at combining drug development and manufacturing solutions for their clientele. Through this alliance, their goal is to deliver swift, comprehensive drug development and manufacturing solutions designed to improve efficiency, decrease expenses, and simplify biopharmaceutical production for clients.

Who Are The Key Market Participants In The Biopharmaceutical CMO Market?

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

Access The Complete Biopharmaceutical CMO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Which Region Contributes The Most To The Biopharmaceutical CMO Market?

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biopharmaceutical CMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

Biopharmaceuticals Contract Manufacturing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Lyophilization Services For Biopharmaceuticals Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

Biopharmaceutical Third Party Logistics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The COVID-19 Saliva Screening Test Potential Market In 2026 And 2030?

The potential market size for covid-19 saliva screening tests has demonstrated robust growth over recent years. This market is projected to expand from $4.28 billion in 2025 to $4.69 billion in 2026, at a compound annual growth rate (CAGR) of 9.5%. The historical growth in this sector is attributable to the discomfort associated with swab-based testing, the imperative for frequent screening, concerns regarding infection control, the demand for scalable testing solutions, and responses to public health emergencies.

The potential market size for covid-19 saliva screening tests is expected to demonstrate significant expansion in the coming years. It is projected to achieve a value of $6.46 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. The impetus for this growth during the forecast period can be attributed to future pandemic preparedness strategies, the increasing prevalence of decentralized diagnostics, the expansion of workplace testing, the demand for cost-effective mass screening, and continuous innovation in saliva-based technologies. Prominent trends anticipated within the forecast period include a general shift towards non-invasive testing methods, the broadening of large-scale community screening efforts, a rising acceptance of self-collection testing, its deployment in high-traffic public locations, and its integration with comprehensive workplace safety programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

What Major Factors Are Driving The COVID-19 Saliva Screening Test Potential Market Forward?

The rise in healthcare expenditure is anticipated to advance the growth of the COVID-19 saliva screening test potential market moving forward. Healthcare expenditure refers to the total funds dedicated to health-related products and services, including prescription drugs, hospital stays, doctor visits, medical equipment, and public health campaigns. This expenditure is escalating due to various elements like minimally invasive surgeries, cutting-edge diagnostic tools, increased research and development for new drugs, utilization of healthcare services, and specialty medications. Greater healthcare spending can offer the essential resources and backing to capitalize on the full capabilities of COVID-19 saliva screening tests, leading to more efficient pandemic management and enhanced public health outcomes. For instance, in December 2024, as per the U.S. Centers for Medicare & Medicaid Services (CMS), a US-based federal health agency, national health-care spending saw an increase of 7.5%, amounting to US $4.9 trillion, when compared to the prior year. Thus, the increasing healthcare expenditure is fueling the growth of the COVID-19 saliva screening test potential market.

Which Segments Define The COVID-19 Saliva Screening Test Potential Market Segment Structure?

The covid-19 saliva screening test potential market covered in this report is segmented –

1) By Location: Travel Stations, Sports Arenas, Entertainment Venues, Corporate Campus Environments, Universities And Colleges, Factories, Other Locations

2) By Technology: Fluorescence-Labelled Antigen, RT-PCR, CRISPR-Cas9

3) By Mode Of Testing: Centralized Testing, Decentralized Testing

Subsegments:

1) By Travel Stations: Airports, Train Stations, Bus Stations, Seaports

2) By Sports Arenas: Stadiums, Arenas, Event Halls

3) By Entertainment Venues: Theaters, Concert Halls, Amusement Parks, Nightclubs

4) By Corporate Campus Environments: Offices, Corporate Campuses, Business Parks

5) By Universities And Colleges: Higher Education Campuses, Research Institutions, Student Housing Areas

6) By Factories: Manufacturing Plants, Production Facilities, Industrial Sites

7) By Other Locations: Healthcare Facilities, Government Buildings, Public Transportation Hubs, Shopping Centers

Which Trends Are Impacting The Progress Of The COVID-19 Saliva Screening Test Potential Market?

Major companies operating in the COVID-19 saliva screening test market are focused on developing innovative technologies, such as data-sharing platforms, to enhance real-time communication and collaboration among healthcare providers, laboratories, and public health authorities. This ultimately improves the efficiency and accuracy of testing, tracking, and response efforts during the pandemic. Data-sharing platforms are digital systems that facilitate the secure exchange of data among various stakeholders like healthcare providers, researchers, and organizations, enabling collaboration and information access to improve decision-making, efficiency, and outcomes across sectors. For instance, in May 2024, Mount Sinai Health System, a US-based healthcare network, launched the Center for Healthcare Readiness. This Center concentrates on improving strategies for public health emergency response, ensuring healthcare systems can effectively handle large-scale crises such as pandemics or natural disasters. It aims to enhance the capacity of the Mount Sinai Health System and collaborate with local, regional, and federal partners to develop comprehensive preparedness plans.

Who Are The Established Players Within The COVID-19 Saliva Screening Test Potential Market?

Major companies operating in the covid-19 saliva screening test potential market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, University of North Carolina at Chapel Hill, Hologic Inc., Beaumont Health, PerkinElmer Inc., Quidel Corporation, University of Illinois at Urbana-Champaign, Cepheid, Seegene Inc., ARUP Laboratories, Vatic Health Limited, Ambry Genetics Corporation, LumiraDx Ltd., Yale School of Public Health, Gravity Diagnostics, Psomagen Inc., Fluidigm Corporation, Phosphorus Diagnostics LLC, DxTerity Diagnostics Inc., University of Notre Dame, MOgene

Get The Full COVID-19 Saliva Screening Test Potential Market Report:

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Which Region Holds The Highest Market Share In The COVID-19 Saliva Screening Test Potential Market?

North America was the largest region in the COVID-19 saliva screening test potential market in 2025. The regions covered in the covid-19 saliva screening test potential market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized COVID-19 Saliva Screening Test Potential Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Browse Through More Reports Similar to the Global COVID-19 Saliva Screening Test Potential Market 2026, By The Business Research Company

Artificial Saliva Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-saliva-global-market-report

Covid 19 Antigen Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-antigen-test-global-market-report

Covid 19 Rapid Test Kits Market 2026

https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Biopharmaceutical CMO Market Over The 2026–2030 Period?

The biopharmaceutical CMO market has observed rapid expansion in recent years. Its valuation is anticipated to climb from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to the escalating development of biologics pipelines, an increase in clinical trial activities, a heightened demand for adaptable manufacturing capacity, a rise in biosimilar approvals, and the presence of specialized biomanufacturing expertise.

The biopharmaceutical cmo market size is anticipated to experience swift expansion over the coming years. This market is projected to reach $54.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period is primarily driven by escalating investments in advanced biologics, a surging need for rapid scale-up manufacturing, the broadening of personalized therapies, increasing integration of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for this period encompass the increased outsourcing of biologics manufacturing, a growing requirement for biosimilar production services, wider application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and a heightened focus on comprehensive, end-to-end cmo capabilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

What Key Factors Are Affecting The Biopharmaceutical CMO Market Demand?

The expanding prevalence of chronic illnesses is anticipated to drive expansion within the biopharmaceutical CMO market in the future. These are enduring health conditions that remain throughout an individual’s life, frequently advancing gradually and necessitating continuous medical care. Biopharmaceutical CMOs are capable of improving efforts against chronic diseases by accelerating drug development, guaranteeing economical production, and upholding stringent quality benchmarks, consequently boosting the availability and economic viability of crucial medicines. For instance, in January 2024, the World Health Organization, an intergovernmental organization located in Switzerland, reported that the burden from noncommunicable diseases, primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to escalate. These diseases cause 41 million deaths annually, accounting for 74% of all deaths and the majority of premature mortality globally, with low- and middle-income countries bearing the greatest burden. Consequently, the growing prevalence of chronic diseases propels the biopharmaceutical CMOs market.

Which Segments Define The Biopharmaceutical CMO Market Segment Structure?

The biopharmaceutical cmo market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Source: Mammalian, Non-Mammalian

3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

Subsegments:

1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

What Trends Are Influencing Changes In The Biopharmaceutical CMO Market?

Leading firms within the biopharmaceutical CMO market are increasingly engaging in strategic alliances to create novel biopharmaceutical products. Such collaborations aid biopharmaceutical CMO organizations by merging assets and specialized knowledge, boosting research and development capacities, broadening market presence, and hastening product launch, which ultimately fosters innovation and expansion in the biopharmaceutical CMO sector. An example of this is the partnership formed in May 2024 between BioConnection, a contract manufacturing company situated in the Netherlands, and AGC Biologics, a contract development and manufacturing company from the US. Through this alliance, their objective is to provide an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby quickening schedules and streamlining procedures for those developing drugs.

Who Are The Established Players Within The Biopharmaceutical CMO Market?

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

Get The Full Biopharmaceutical CMO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Where Is The Biopharmaceutical CMO Market Most Concentrated Geographically?

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biopharmaceutical CMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Medical Biomimetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Biopharmaceutical CMO Market Over The 2026–2030 Period?

The biopharmaceutical CMO market has observed rapid expansion in recent years. Its valuation is anticipated to climb from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to the escalating development of biologics pipelines, an increase in clinical trial activities, a heightened demand for adaptable manufacturing capacity, a rise in biosimilar approvals, and the presence of specialized biomanufacturing expertise.

The biopharmaceutical cmo market size is anticipated to experience swift expansion over the coming years. This market is projected to reach $54.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period is primarily driven by escalating investments in advanced biologics, a surging need for rapid scale-up manufacturing, the broadening of personalized therapies, increasing integration of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for this period encompass the increased outsourcing of biologics manufacturing, a growing requirement for biosimilar production services, wider application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and a heightened focus on comprehensive, end-to-end cmo capabilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

What Key Factors Are Affecting The Biopharmaceutical CMO Market Demand?

The expanding prevalence of chronic illnesses is anticipated to drive expansion within the biopharmaceutical CMO market in the future. These are enduring health conditions that remain throughout an individual’s life, frequently advancing gradually and necessitating continuous medical care. Biopharmaceutical CMOs are capable of improving efforts against chronic diseases by accelerating drug development, guaranteeing economical production, and upholding stringent quality benchmarks, consequently boosting the availability and economic viability of crucial medicines. For instance, in January 2024, the World Health Organization, an intergovernmental organization located in Switzerland, reported that the burden from noncommunicable diseases, primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to escalate. These diseases cause 41 million deaths annually, accounting for 74% of all deaths and the majority of premature mortality globally, with low- and middle-income countries bearing the greatest burden. Consequently, the growing prevalence of chronic diseases propels the biopharmaceutical CMOs market.

Which Segments Define The Biopharmaceutical CMO Market Segment Structure?

The biopharmaceutical cmo market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Source: Mammalian, Non-Mammalian

3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

Subsegments:

1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

What Trends Are Influencing Changes In The Biopharmaceutical CMO Market?

Leading firms within the biopharmaceutical CMO market are increasingly engaging in strategic alliances to create novel biopharmaceutical products. Such collaborations aid biopharmaceutical CMO organizations by merging assets and specialized knowledge, boosting research and development capacities, broadening market presence, and hastening product launch, which ultimately fosters innovation and expansion in the biopharmaceutical CMO sector. An example of this is the partnership formed in May 2024 between BioConnection, a contract manufacturing company situated in the Netherlands, and AGC Biologics, a contract development and manufacturing company from the US. Through this alliance, their objective is to provide an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby quickening schedules and streamlining procedures for those developing drugs.

Who Are The Established Players Within The Biopharmaceutical CMO Market?

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

Get The Full Biopharmaceutical CMO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Where Is The Biopharmaceutical CMO Market Most Concentrated Geographically?

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biopharmaceutical CMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Medical Biomimetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Biopharmaceutical CMO Market By 2030 Starting From Its 2026 Size?

The biopharmaceutical cmo market has experienced rapid growth in its size over recent years. It is projected to expand from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historic expansion can be linked to increasing biologics pipeline development, expansion of clinical trial activity, a rising demand for flexible manufacturing capacity, the growth of biosimilar approvals, and the availability of specialized biomanufacturing expertise.

The biopharmaceutical CMO market size is anticipated to undergo substantial growth over the next few years. It is projected to expand to $54.54 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.2%. The expansion throughout the forecast period is attributable to several factors, including increased investments in cutting-edge biologics, a surging need for accelerated scale-up manufacturing, the proliferation of personalized therapies, the increasing adoption of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for the forecast period comprise an increase in the outsourcing of biologics manufacturing, a rising call for biosimilar production services, the growing application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and an enhanced concentration on comprehensive CMO capabilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

What Primary Drivers Are Shaping The Development Of The Biopharmaceutical CMO Market?

The increasing prevalence of chronic diseases is set to drive the expansion of the biopharmaceutical CMO market in the future. These long-term health conditions persist throughout an individual’s life, often progressing slowly and requiring continuous medical attention. Biopharmaceutical CMOs are instrumental in addressing chronic diseases by accelerating the development of drugs, providing cost-effective manufacturing solutions, and upholding high-quality benchmarks, thereby making life-saving medications more accessible and affordable. As an illustration, in January 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that the burden of noncommunicable diseases, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to grow. These diseases are responsible for 41 million deaths every year, representing 74% of all deaths and the majority of premature mortality globally, with the most significant consequences observed in low- and middle-income countries. Hence, the rising burden of chronic diseases is a key driver for the biopharmaceutical CMOs market.

Which Segment Categories Define The Biopharmaceutical CMO Market?

The biopharmaceutical cmo market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Source: Mammalian, Non-Mammalian

3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

Subsegments:

1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

Which Trends Are Influencing The Biopharmaceutical CMO Market?

Leading entities within the biopharmaceutical CMO market are increasingly engaging in strategic collaborations to advance the creation of novel biopharmaceutical offerings. Such alliances prove beneficial for biopharmaceutical CMO organizations by facilitating the pooling of assets and specialized knowledge, thereby boosting research and development capacities, broadening market presence, and hastening product commercialization. This ultimately propels innovation and expansion across the biopharmaceutical CMO sector. An illustrative example occurred in May 2024, when BioConnection, a Netherlands-based contract manufacturing company, formed a partnership with AGC Biologics, a US-based contract development and manufacturing company. Through this collaboration, their objective is to offer an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby shortening project durations and streamlining procedures for drug innovators.

Who Are The Top Companies Competing In The Biopharmaceutical CMO Market?

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

Read the full biopharmaceutical cmo market report here:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

How Does The Biopharmaceutical CMO Market Perform Across Major Global Regions?

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biopharmaceutical CMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

Biopharmaceuticals Contract Manufacturing Global Market Report

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Lyophilization Services For Biopharmaceuticals Global Market Report

https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

Biopharmaceutical Third Party Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model